NCT00647062

AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer

Study identifier: NCT00647062
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)

Eligibility:

• Documented deleterious BRCA1/BRCA2 germline mutation or BRCAPRO score ≥ 30%
• Sporadic ovarian serous epithelial cancer with negative family history, BRCAPRO score ≤ 20%, or negative BRCA1/BRCA2 mutation
• Metastatic or unresectable disease for which standard curative measures do not exist or are no longer effective
• Measurable and/or evaluable disease
• At least 6 months since prior platinum drugs

• Patients with platinum-resistant disease are eligible

Type of study:

Phase I study

Treatment:

Participants receive a combination of olaparib and carboplatin. 

Study site:

Maryland

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Contact: Laura D.Otten, R.N., B.S.N., O.C.N.
Medical Oncology Referral Coordinator 301-451-1228
1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

Web design by Rareheron Web Design